Sanofi
Real-time prices from Yahoo Finance's public feed. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Latest news
All SNY news ›Regeneron, Sanofi deepen antibody collaboration with expanded alliance
The latest announcement is out from Regeneron ( (REGN) ). The most recent analyst rating on (REGN) stock is a Buy with a $950.00 price target. To see the full list of analyst forecasts on Regeneron stock, see the REGN Stock Forecast page.…
Novavax (NVAX) Stock Pops 16% On Sanofi Vaccine News
Novavax stock climbed about 16% on October 9. The move pushed the biotech back toward the upper end of its 52-week range. The gain centers on fresh progress in Novavax’s partnership with Sanofi. Regulators in Belgium, Germany, and Portugal…
J&J, Bayer, Sanofi, GE: This Week in Healthcare
October marks the beginning of global Menopause Awareness Month, a moment dedicated to recognising the effects menopause has on billions of lives, careers and overall health. But despite advocacy efforts, many common menopause symptoms…
Sanofi (SNYNF) Gets a Buy from Jefferies
In a report released today, Michael Leuchten from Jefferies maintained a Buy rating on Sanofi, with a price target of €100.00. According to TipRanks, Leuchten is an analyst with an average return of -4.3% and a 47.17% success rate. In…
Expanded Sanofi agreement particularly favorable for Regeneron, says TD Cowen
TD Cowen analyst Tyler Van Buren reiterated a Buy rating and $960 price target on Regeneron (REGN), saying the expanded agreement with Sanofi (S... Expanded Sanofi agreement particularly favorable for Regeneron, says TD Cowen TD Cowen…
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (OtherSNYNF), Sagimet Biosciences, Inc. Class A (SGMT) and Eli Lilly & Co (LLY)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sanofi (SNYNF), Sagimet Biosciences, Inc. Class A (SGMT) and Eli Lilly & Co (LLY). In a report released today, Trung Huynh from RBC Capital…
J.P. Morgan Sticks to Its Hold Rating for Sanofi (SNYNF)
In a report released today, Richard Vosser from J.P. Morgan maintained a Hold rating on Sanofi, with a price target of €95.00. According to TipRanks, Vosser is ranked #4497 out of 12443 analysts. In addition to J.P. Morgan, Sanofi also…
Expanded Sanofi Alliance And New Pipeline Data Could Be A Game Changer For Regeneron (REGN)
In early October 2026, Regeneron Pharmaceuticals reported new clinical data across oncology and obesity programs and expanded its long-running antibody alliance with Sanofi, which includes US$1.00 billion upfront and potential future…
Regeneron sees nearly $0.18 per share earnings headwind after Sanofi deal
Regeneron (REGN) sees a ~$0.18 per share impact on earnings in Q3 due to an acquired in-process R&D charge after an expanded deal with Sanofi (SNY). Read more here. - Days after announcing an expanded collaboration with its French partner…
TRrexBio’s IPO Bags $116M to Bring the Immune System Back Into Balance
Eli Lilly-partnered TRexBio will apply the IPO proceeds toward clinical development of molecules designed to activate regulatory T cells to mediate immune responses and inflammation. Meanwhile, Retension Pharmaceuticals will use its IPO…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
tradingview.com107
-
marketscreener.com99
-
finance.yahoo.com75
-
seekingalpha.com40
-
biospace.com38
Measured across the 4SiliconValley news index. Headline tone is a simple word-based reading of the latest 120 headlines, not a forecast.